Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M98,904Revenue (TTM) $M25,242Net Margin (%)24.1Altman Z-Score2.0
Enterprise Value $M128,715EPS (TTM) $3.7Operating Margin %36.2Piotroski F-Score6
P/E(ttm)16.5Beneish M-Score-2.3Pre-tax Margin (%)30.9Higher ROA y-yY
Price/Book15.410-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %0.7Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow14.4y-y EBITDA Growth Rate %94.2ROA % (ttm)10.3Higher Current Ratio y-yN
Dividend Yield %3.7PEG23.0ROE % (ttm)119Less Shares Outstanding y-yY
Payout Ratio %60.0Shares Outstanding M1,625ROIC % (ttm)23.1Gross Margin Increase y-yN

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVNWQ Managers 2016-09-30 Reduce-0.44%$61.92 - $67.39
($64.74)
$ 60.86-6%Reduce -73.90%146,743
ABBVJoel Greenblatt 2016-09-30 Reduce-0.16%$61.92 - $67.39
($64.74)
$ 60.86-6%Reduce -24.43%684,356
ABBVDavid Dreman 2016-09-30 Reduce-0.03%$61.92 - $67.39
($64.74)
$ 60.86-6%Reduce -5.52%15,019
ABBVMario Gabelli 2016-09-30 Reduce$61.92 - $67.39
($64.74)
$ 60.86-6%Reduce -42.78%20,196
ABBVKen Fisher 2016-09-30 Reduce$61.92 - $67.39
($64.74)
$ 60.86-6%Reduce -1.35%684,042
ABBVNWQ Managers 2016-06-30 Reduce-0.2%$57.12 - $65.09
($60.87)
$ 60.86-0%Reduce -28.08%562,288
ABBVJoel Greenblatt 2016-06-30 Add0.19%$57.12 - $65.09
($60.87)
$ 60.86-0%Add 40.22%905,598
ABBVDavid Dreman 2016-06-30 Reduce-0.1%$57.12 - $65.09
($60.87)
$ 60.86-0%Reduce -47.95%15,897
ABBVKen Fisher 2016-06-30 Reduce-0.01%$57.12 - $65.09
($60.87)
$ 60.86-0%Reduce -6.71%693,394
ABBVMario Gabelli 2016-06-30 Reduce$57.12 - $65.09
($60.87)
$ 60.86-0%Reduce -0.46%35,296
ABBVJoel Greenblatt 2016-03-31 Add0.28%$51.18 - $59.24
($55.77)
$ 60.869%Add 216.32%645,835
ABBVJohn Paulson 2016-03-31 Sold Out -0.05%$51.18 - $59.24
($55.77)
$ 60.869%Sold Out0
ABBVDavid Dreman 2016-03-31 Add0.03%$51.18 - $59.24
($55.77)
$ 60.869%Add 16.28%30,542
ABBVNWQ Managers 2016-03-31 Add0.02%$51.18 - $59.24
($55.77)
$ 60.869%Add 3.64%781,850
ABBVKen Fisher 2016-03-31 Reduce-0.02%$51.18 - $59.24
($55.77)
$ 60.869%Reduce -20.51%743,284
ABBVDodge & Cox 2016-03-31 Reduce$51.18 - $59.24
($55.77)
$ 60.869%Reduce -0.07%33,232
ABBVMario Gabelli 2016-03-31 Reduce$51.18 - $59.24
($55.77)
$ 60.869%Reduce -12.66%35,460
ABBVNWQ Managers 2015-12-31 Reduce-0.65%$48.27 - $64.13
($57.69)
$ 60.865%Reduce -50.59%754,413
ABBVFirst Eagle Investment 2015-12-31 Sold Out -0.14%$48.27 - $64.13
($57.69)
$ 60.865%Sold Out0
ABBVJoel Greenblatt 2015-12-31 Add0.08%$48.27 - $64.13
($57.69)
$ 60.865%Add 179.54%204,171
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE WILLIAM JEVP, CFO 2016-12-02Sell6,600$59.192.82view
HURWICH THOMAS A.VP, Controller 2016-11-16Sell3,100$62-1.84view
Schumacher Laura JExecutive Vice President 2016-09-07Sell50,000$65-6.37view
Schumacher Laura JExecutive Vice President 2016-06-24Sell186,106$60.031.38view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-06-02Sell285,953$63.82-4.64view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-05-11Sell39,000$63.8-4.61view
HURWICH THOMAS A.VP, Controller 2016-05-10Sell6,000$63.59-4.29view
RICHMOND TIMOTHY J.SVP, Human Resources 2016-05-10Sell21,583$63.52-4.19view
ALBAN CARLOSEVP, Commercial Operations 2016-05-10Sell47,438$63.52-4.19view
Schumacher Laura JExecutive Vice President 2016-03-08Sell25,000$56.098.5view

Press Releases about ABBV :

Quarterly/Annual Reports about ABBV:

News about ABBV:

Articles On GuruFocus.com
FDA Orphan Drug Designation for AbbVie's Risankizumab Dec 01 2016 
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016 
Enanta Pharmaceuticals Releases Results Nov 22 2016 
Abbvie Ends Development Program With Halozyme Nov 21 2016 
How a 15% Decline Is a Gift to Income Investors Nov 21 2016 
AbbVie: Treatment Cured Chronic HCV Patients Nov 16 2016 
AbbVie's Humira a Step Closer to Approval in Europe Nov 15 2016 
Merck Reports Triple-Combo Results Nov 14 2016 
RA Drug Comparison Yields Mixed Results Nov 14 2016 

More From Other Websites
Leukemia Treatment Achieves Promising Results Dec 05 2016
Bond Sell-Off Could Be Huge for Stocks: 4 Analyst Top Pick Dividend Stocks to Buy Now Dec 05 2016
AbbVie and Johns Hopkins to Collaborate on Cancer Research Dec 05 2016
AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer... Dec 05 2016
2:14 am AbbVie reports 5-year analysis and long-term RESONATE-2 follow-up; 89% with CLL/SLL achieve... Dec 05 2016
Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two... Dec 04 2016
IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and... Dec 03 2016
[$$] New Tax Rules on Corporate Inversions Face Uncertain Future Dec 03 2016
[$$] Tax Rules on Corporate Inversions Face Uncertain Future Dec 02 2016
Uterine Fibroids Segment May Offer Opportunity for NBIX Dec 02 2016
AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy Dec 02 2016
Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix Dec 02 2016
Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta? Dec 02 2016
Billionaire Larry Robbins Confidently Piles Into CBS, Anthem, As Merger Battles Continue Dec 02 2016
Label Expansion May Boost Venclexta’s Growth Prospects Dec 02 2016
What Do Analysts Recommend for Gilead Sciences Stock? Dec 02 2016
FDA Orphan Drug Designation for AbbVie's Risankizumab Dec 01 2016
OraSure Stock Sets Up For Buy Point On Hep C Contract, Helix Win Dec 01 2016
Is AbbVie Inc (ABBV) A Good Stock To Buy? Dec 01 2016
AbbVie’s ABT-494 May Become Standard of Care in Immunology Dec 01 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)